Through the 90-day period concluding January 10, 2026, Cullinan Therapeutics's top three insider stakeholders include TenPercentOwner Capital Management Lp Lynx1 (8.96Mn shares), Director Ansbert Gadicke (7.89Mn shares), TenPercentOwner Oncology Impact Fund L.P. Ubs (7.65Mn shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Capital Management Lp Lynx1 | 8,963,500 | 30 Oct, 2025 | |
| Ansbert Gadicke | 7,892,819 | 20 Sep, 2021 | |
| Oncology Impact Fund L.P. Ubs | 7,648,268 | 20 Sep, 2021 | |
| Vision Scs F2 | 1,255,963 | 04 Aug, 2022 | |
| Bioscience I 2017 Ltd F2 | 537,392 | 23 Jun, 2022 | |
| Nadim Ahmed | President And Ceo | 420,699 | 29 Dec, 2025 |
| Corrine Savill | Chief Business Officer | 240,990 | 21 Feb, 2025 |
| Morana Jovan-Embiricos | 207,803 | 28 Jun, 2022 | |
| Thomas Ebeling | 186,653 | 11 Jun, 2024 | |
| Jeffrey Alan Jones | Chief Medical Officer | 169,532 | 19 Dec, 2025 |
| Jacquelyn L Sumer | Chief Legal Officer | 135,432 | 19 Dec, 2025 |
| Jeffrey Trigilio | Chief Financial Officer | 133,919 | 23 Feb, 2024 |
| Jennifer Michaelson | Chief Scientific Officer | 132,635 | 22 Dec, 2025 |
| Patrick Baeuerle | Chief Scientific Officer | 76,000 | 21 Feb, 2023 |
| Leigh Zawel | Nan | 69,785 | 15 Feb, 2022 |
| Partners L P/Il Bvf | 64,161 | 19 Jan, 2023 | |
| Mary Kay Fenton | Chief Financial Officer | 62,028 | 05 Jan, 2026 |
| Raymond T Keane | Chief Legal Officer | 24,124 | 15 Feb, 2022 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 31 Dec, 2025 | Mary Kay Fenton | Common Stock | A | 27 | $6.49 | 62,028 | D | A |
| 23 Dec, 2025 | Nadim Ahmed | Common Stock | D | 9,922 | $10.01 | 420,699 | D | S |
| 19 Dec, 2025 | Jennifer Michaelson | Common Stock | D | 1,345 | $10.01 | 132,635 | D | S |
| 18 Dec, 2025 | Jennifer Michaelson | Common Stock | D | 2,898 | $9.67 | 133,980 | D | S |
| 18 Dec, 2025 | Jacquelyn L Sumer | Common Stock | D | 3,480 | $9.67 | 135,432 | D | S |
| 18 Dec, 2025 | Jeffrey Alan Jones | Common Stock | D | 4,632 | $9.67 | 169,532 | D | S |
| 15 Dec, 2025 | Jennifer Michaelson | Common Stock | D | 995 | $11.90 | 136,878 | D | S |
| 12 Dec, 2025 | Jennifer Michaelson | Common Stock | D | 2,148 | $12.38 | 137,873 | D | S |
| 24 Nov, 2025 | Jennifer Michaelson | Common Stock | D | 4,000 | $12.30 | 138,004 | D | S |
| 28 Oct, 2025 | Capital Management Lp Lynx1 | Common stock, $0.0001 par value per share | A | 165,667 | $8.40 | 8,963,500 | I | P |
| 17 Oct, 2025 | Capital Management Lp Lynx1 | Common Stock | A | 32,217 | $7.84 | 8,797,833 | I | P |
| 16 Oct, 2025 | Capital Management Lp Lynx1 | Common Stock | A | 150,000 | $8.86 | 8,765,616 | I | P |
| 15 Oct, 2025 | Capital Management Lp Lynx1 | Common Stock | A | 51,500 | $7.94 | 8,615,616 | I | P |
| 14 Oct, 2025 | Capital Management Lp Lynx1 | Common stock, $0.0001 par value per share ("Common Stock") | A | 15,032 | $7.59 | 8,564,116 | I | P |
| 10 Oct, 2025 | Capital Management Lp Lynx1 | Common Stock | A | 277,298 | $7.36 | 8,549,084 | I | P |
| 09 Oct, 2025 | Capital Management Lp Lynx1 | Common Stock | A | 626,043 | $6.70 | 8,271,786 | I | P |
| 08 Oct, 2025 | Capital Management Lp Lynx1 | Common stock, $0.0001 par value per share ("Common Stock") | A | 556,300 | $6.46 | 7,645,743 | I | P |
| 25 Feb, 2025 | Nadim Ahmed | Common Stock | D | 12,529 | $8.53 | 430,621 | D | S |
| 25 Feb, 2025 | Jennifer Michaelson | Common Stock | D | 3,756 | $8.53 | 142,004 | D | S |
| 25 Feb, 2025 | Jacquelyn L Sumer | Common Stock | D | 3,756 | $8.53 | 136,895 | D | S |